Novel HDAC inhibitor offers hope in heavily pretreated HL patients

Article

Phase II study results are encouraging because this patient population generally sees a median of five prior lines of therapy including transplants, explained Jeffrey M. Besterman, MD, PhD, executive vice president and chief scientific officer for MethylGene, the developer of mocetinostat (MGCD0103).

ORLANDO, FLA-Mocetinostat (MGCD0103), an experimental isotype-selective histone deacetylase (HDAC) inhibitor, produced a 30% response rate in patients with relapsed or refractory Hodgkin’s lymphoma. Mocetinostat is the first HDAC inhibitor of its class to show reasonable clinical activity in a heavily pretreated, relapsed, or refractory [HL] population, said study leader Anas Younes, MD. Moreover, it worked as a single agent.

“It is a more restricted HDAC inhibitor and preferentially inhibits class I and class IV HDACs but has no activity in class II enzymes,” added Dr. Younes, a professor of medicine in the department of lymphoma at Houston’s M.D. Anderson Cancer Center.

The open-label phase II trial had 51 adults (median age 33) who had all failed multiple therapies, including chemotherapy, radiotherapy, immunotherapy, hormone therapy, and prior autologous or allogeneic stem cell transplant. The patients received mocetinostat at a starting dose of 110 mg (23 patients) or 85 mg (28 patients), three times a week in four-week cycles.

Results in 43 of 51 patients were evaluated. The success rate was defined as complete response, partial response, and stable disease lasting at least six cycles, and came in at 35%. Two patients showed a complete response, 12 patients showed a partial response, and one patient had durable stable disease. In the intent-to-treat population (51 patients) the success rate was 29% (ASH 2010 abstract 1763).

These results are particularly encouraging because this patient population generally sees a median of five prior lines of therapy including transplants, explained Jeffrey M. Besterman, MD, PhD, executive vice president and chief scientific officer for Methylgene, the developer of mocetinostat.

“This is a heavily pretreated population that does not have a very good prognosis. So for them to show that kind of response, and with a single oral agent given just three times a week, is pretty impressive,” he told Oncology NEWS International.

Importantly, minimal hematologic activity was observed with mocetinostat, Dr. Besterman pointed out. “Unlike many of the other HDAC inhibitors, this agent is more selective and its efficacy seems to be better than most of the others. What is really demonstrable is the safety profile of this agent. Other HDAC inhibitors used in this setting can produce thrombocytopenia in 50% to 75% of patients,” he said. “In our study, only about 20% of the patients had thrombocytopenia with mocetinostat. I think that’s the hallmark of the selectivity that we have built into this molecule. It really minimizes the thrombocytopenia.”

Dr. Besterman said that mocetinostat will be studied in other lymphomas, including an ongoing trial in follicular lymphoma.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content